SOPH vs. VTYX, CRBU, FHTX, GLUE, RPTX, TARS, FDMT, DNA, AUTL, and IMTX
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Ventyx Biosciences (VTYX), Caribou Biosciences (CRBU), Foghorn Therapeutics (FHTX), Monte Rosa Therapeutics (GLUE), Repare Therapeutics (RPTX), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), Ginkgo Bioworks (DNA), Autolus Therapeutics (AUTL), and Immatics (IMTX). These companies are all part of the "medical" sector.
Ventyx Biosciences (NASDAQ:VTYX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.
In the previous week, SOPHiA GENETICS had 3 more articles in the media than Ventyx Biosciences. MarketBeat recorded 5 mentions for SOPHiA GENETICS and 2 mentions for Ventyx Biosciences. SOPHiA GENETICS's average media sentiment score of 1.61 beat Ventyx Biosciences' score of 0.76 indicating that Ventyx Biosciences is being referred to more favorably in the media.
Ventyx Biosciences received 11 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.73% of users gave SOPHiA GENETICS an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Ventyx Biosciences has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Ventyx Biosciences currently has a consensus target price of $21.75, indicating a potential upside of 355.02%. SOPHiA GENETICS has a consensus target price of $8.00, indicating a potential upside of 60.32%. Given SOPHiA GENETICS's higher possible upside, equities research analysts plainly believe Ventyx Biosciences is more favorable than SOPHiA GENETICS.
SOPHiA GENETICS has higher revenue and earnings than Ventyx Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
Ventyx Biosciences has a net margin of 0.00% compared to Ventyx Biosciences' net margin of -113.71%. Ventyx Biosciences' return on equity of -47.56% beat SOPHiA GENETICS's return on equity.
Summary
SOPHiA GENETICS beats Ventyx Biosciences on 9 of the 17 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
